Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

DC Vaccine (TH1 Dendritic Cell Immunotherapy) for the Treatment of Cutaneous Angiosarcoma

Trial Status: withdrawn

This phase I trial tests the safety, side effects, and best dose of a dendritic cell (DC) vaccine (TH1 dendritic cell vaccine) in treating patients with cutaneous (skin) angiosarcoma. The vaccine (which contains a messenger ribonucleic acid plus lysate-loaded dendritic cell vaccine) is made from the patients' own blood and tumor cells. The cells are collected and then genetically modified (changed) in a laboratory to make the study vaccine. This DC vaccine may help patients' immune system "attack" the cancer better.